Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Nutrients ; 14(3)2022 Jan 18.
Artigo em Inglês | MEDLINE | ID: mdl-35276769

RESUMO

Different cocoa populations have demonstrated a protective role in a rat model of allergic asthma by attenuating the immunoglobulin (Ig) E synthesis and partially protecting against anaphylactic response. The aim of this study was to ascertain the effect of diets containing two native Peruvian cocoa populations ("Amazonas Peru" or APC, and "Criollo de Montaña" or CMC) and an ordinary cocoa (OC) on the bronchial compartment and the systemic and mucosal immune system in the same rat model of allergic asthma. Among other variables, cells and IgA content in the bronchoalveolar lavage fluid (BALF) and serum anti-allergen antibody response were analyzed. The three cocoa populations prevented the increase of the serum specific IgG1 (T helper 2 isotype). The three cocoa diets decreased asthma-induced granulocyte increase in the BALF, which was mainly due to the reduction in the proportion of eosinophils. Moreover, both the OC and CMC diets were able to prevent the leukocyte infiltration caused by asthma induction in both the trachea and nasal cavity and decreased the IgA in both fecal and BALF samples. Overall, these results highlight the potential of different cocoa populations in the prevention of allergic asthma.


Assuntos
Asma , Cacau , Chocolate , Animais , Imunidade , Peru , Ratos
2.
Nanomedicine ; 19: 115-125, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31004811

RESUMO

Pioglitazone (PGZ) is a peroxisome proliferator-activated receptor agonist. Its role in the inflammatory response modulation paves the way for additional therapeutic applications. The purpose of this study was to develop a pioglitazone nanoemulsion (PGZ-NE) in order to investigate its anti-inflammatory efficacy on the skin. To that end, an NE vehicle developed for skin delivery was optimized and characterized. The resulting PGZ-NE showed good anti-inflammatory efficacy by decreasing the expression of inflammatory cytokines IL-6, IL-1ß and TNF-α. The properties of the developed nanocarrier allowed achievement of a high permeation flux of PGZ through the skin as well as a high retained amount in the skin, likely due to the depot effect of ingredients, which assured a prolonged local action, with good skin tolerability among participating individuals. Consequently, these results suggest that PGZ-NE may be used as an alternative treatment for inflammatory skin diseases such as rosacea, atopic dermatitis or psoriasis.


Assuntos
Emulsões/química , Inflamação/tratamento farmacológico , Nanopartículas/química , Pioglitazona/uso terapêutico , Dermatopatias/tratamento farmacológico , Adulto , Animais , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêutico , Citocinas/metabolismo , Liberação Controlada de Fármacos , Feminino , Humanos , Inflamação/patologia , Camundongos Endogâmicos BALB C , Nanopartículas/ultraestrutura , Permeabilidade , Pioglitazona/efeitos adversos , Pioglitazona/farmacologia , Reologia , Pele/efeitos dos fármacos , Pele/patologia , Dermatopatias/patologia , Viscosidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA